|
Instituto Krishna de Medical Sciences Limited (KIMS.NS) Valoración de DCF
IN | Healthcare | Medical - Care Facilities | NSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Krishna Institute of Medical Sciences Limited (KIMS.NS) Bundle
¡Explore el potencial financiero del Instituto de Ciencias Médicas Krishna Limited (KIMSNS) con nuestra calculadora DCF fácil de usar! Ingrese sus predicciones de crecimiento, márgenes y gastos para determinar el valor intrínseco de KIMSNS y dar forma a su enfoque de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,226.5 | 13,299.4 | 16,309.8 | 21,976.8 | 24,981.4 | 30,572.2 | 37,414.1 | 45,787.2 | 56,034.2 | 68,574.4 |
| Revenue Growth, % | 0 | 18.46 | 22.64 | 34.75 | 13.67 | 22.38 | 22.38 | 22.38 | 22.38 | 22.38 |
| EBITDA | 2,555.4 | 3,858.7 | 5,418.9 | 6,514.5 | 6,526.2 | 8,607.2 | 10,533.4 | 12,890.8 | 15,775.7 | 19,306.2 |
| EBITDA, % | 22.76 | 29.01 | 33.22 | 29.64 | 26.12 | 28.15 | 28.15 | 28.15 | 28.15 | 28.15 |
| Depreciation | 706.1 | 695.4 | 726.7 | 1,292.6 | 1,465.5 | 1,695.0 | 2,074.4 | 2,538.6 | 3,106.8 | 3,802.0 |
| Depreciation, % | 6.29 | 5.23 | 4.46 | 5.88 | 5.87 | 5.54 | 5.54 | 5.54 | 5.54 | 5.54 |
| EBIT | 1,849.3 | 3,163.3 | 4,692.2 | 5,221.9 | 5,060.7 | 6,912.1 | 8,459.0 | 10,352.1 | 12,668.9 | 15,504.2 |
| EBIT, % | 16.47 | 23.79 | 28.77 | 23.76 | 20.26 | 22.61 | 22.61 | 22.61 | 22.61 | 22.61 |
| Total Cash | 457.3 | 2,844.4 | 1,899.9 | 1,706.5 | 1,319.8 | 3,066.9 | 3,753.2 | 4,593.2 | 5,621.1 | 6,879.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 1,231.7 | 1,438.7 | 2,697.0 | 3,204.1 | 2,640.2 | 3,231.1 | 3,954.2 | 4,839.2 | 5,922.2 |
| Account Receivables, % | 0 | 9.26 | 8.82 | 12.27 | 12.83 | 8.64 | 8.64 | 8.64 | 8.64 | 8.64 |
| Inventories | 303.8 | 240.9 | 364.3 | 428.7 | 494.4 | 653.0 | 799.2 | 978.0 | 1,196.9 | 1,464.7 |
| Inventories, % | 2.71 | 1.81 | 2.23 | 1.95 | 1.98 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
| Accounts Payable | 1,234.3 | 1,318.7 | 1,295.3 | 1,742.6 | 1,971.5 | 2,731.5 | 3,342.8 | 4,090.9 | 5,006.5 | 6,126.9 |
| Accounts Payable, % | 10.99 | 9.92 | 7.94 | 7.93 | 7.89 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 |
| Capital Expenditure | -519.8 | -944.3 | -1,703.2 | -5,745.3 | -6,473.4 | -4,538.6 | -5,554.4 | -6,797.4 | -8,318.6 | -10,180.3 |
| Capital Expenditure, % | -4.63 | -7.1 | -10.44 | -26.14 | -25.91 | -14.85 | -14.85 | -14.85 | -14.85 | -14.85 |
| Tax Rate, % | 32.52 | 32.52 | 32.52 | 32.52 | 32.52 | 32.52 | 32.52 | 32.52 | 32.52 | 32.52 |
| EBITAT | 1,568.4 | 2,281.3 | 3,416.9 | 3,621.8 | 3,414.8 | 5,067.8 | 6,201.9 | 7,589.9 | 9,288.5 | 11,367.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2,685.3 | 948.0 | 2,086.6 | -1,706.3 | -1,937.1 | 3,389.5 | 2,596.2 | 3,177.3 | 3,888.3 | 4,758.5 |
| WACC, % | 5.22 | 5.19 | 5.19 | 5.18 | 5.17 | 5.19 | 5.19 | 5.19 | 5.19 | 5.19 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 15,169.2 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 4,949 | |||||||||
| Terminal Value | 415,907 | |||||||||
| Present Terminal Value | 322,944 | |||||||||
| Enterprise Value | 338,113 | |||||||||
| Net Debt | 13,084 | |||||||||
| Equity Value | 325,028 | |||||||||
| Diluted Shares Outstanding, MM | 400 | |||||||||
| Equity Value Per Share | 812.29 |
What You Will Receive
- Genuine KIMSNS Data: Preloaded financials – encompassing revenue, expenses, and net income – based on actual and projected metrics.
- Comprehensive Customization: Modify all key parameters (highlighted cells) such as WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalibrations to evaluate the effects of changes on KIMSNS's fair value.
- Flexible Excel Template: Designed for quick adjustments, scenario analysis, and in-depth projections.
- Efficient and Accurate: Bypass the need to create models from square one while ensuring accuracy and adaptability.
Key Features
- Comprehensive KIMSNS Data: Pre-loaded with Krishna Institute of Medical Sciences Limited’s historical performance and future forecasts.
- Customizable Parameters: Modify service rates, patient growth, operational costs, and profit margins as per your needs.
- Interactive Valuation Framework: Automatic recalculations of Net Present Value (NPV) and intrinsic worth driven by your specified inputs.
- Scenario Analysis: Develop various forecasting scenarios to assess a range of valuation results.
- Intuitive Interface: User-friendly layout designed for both experienced professionals and newcomers.
How It Works
- Step 1: Download the prebuilt Excel template featuring data for Krishna Institute of Medical Sciences Limited (KIMSNS).
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Adjust forecasts and assumptions within the editable yellow cells (WACC, growth, margins).
- Step 4: View real-time recalculated outcomes, including the intrinsic value of KIMSNS.
- Step 5: Utilize the results to make well-informed investment decisions or create detailed reports.
Why Select This Calculator for KIMSNS?
- Designed for Experts: A sophisticated tool favored by healthcare analysts, CFOs, and consultants.
- Accurate Data: KIMSNS’s historical and projected financial information is preloaded for precision.
- Scenario Analysis: Easily simulate various forecasts and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance takes you through the entire process.
Who Should Use This Product?
- Medical Students: Explore clinical practices and apply them using real-world case studies.
- Researchers: Integrate advanced healthcare models into your studies or publications.
- Healthcare Investors: Validate your hypotheses and assess valuation metrics for Krishna Institute of Medical Sciences Limited (KIMSNS).
- Healthcare Analysts: Enhance your analysis process with a tailored, ready-to-use valuation model.
- Healthcare Professionals: Understand the financial evaluation methods used for large healthcare organizations like KIMSNS.
Contents of the Template
- Comprehensive DCF Model: An editable template featuring in-depth valuation calculations.
- Real-World Data: Historical and projected financials for Krishna Institute of Medical Sciences Limited (KIMSNS) preloaded for analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis covering profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear and actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.